2019 Novel Coronavirus Infection Clinical Trial
Official title:
An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area
The investigators plan to carry out an experimental study on the preventive effect of recombinant human interferon alpha nasal drops on the infection of 2019 new coronavirus in medical staff.
The investigators plan to carry out an experimental study enrolling more than 2000 medical staff and divide participants into low-risk group and high-risk group according to whether they can directly exposed to 2019-nCOV infected patients. In the low-risk group, participants will be given recombinant human interferon alpha-1b nasal drops (2-3 drops/nostril/ time, 4 times/ day), and in the high-risk group will be given preventive intervention with interferon nasal drops and thymosin-α (thymosin was injected subcutaneously once / week), and the intervention time is 28 days. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04470583 -
Evaluating Clinical Parameters of COVID-19 in Pregnancy
|
||
| Completed |
NCT05364268 -
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
|
||
| Recruiting |
NCT04459351 -
PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs
|
||
| Terminated |
NCT04778059 -
Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19
|
Phase 2 | |
| Withdrawn |
NCT05085574 -
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)
|
Phase 2 | |
| Not yet recruiting |
NCT05722678 -
Study and Analysis of Acute Pancreatitis Complicated With COVID-19
|
||
| Active, not recruiting |
NCT05077332 -
LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
|
Phase 2 | |
| Terminated |
NCT05077969 -
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2)
|
Phase 2 | |
| Recruiting |
NCT05375773 -
Povidone Iodine Nasal Irrigation and Gargling to Reduce Viral Load in Asymptomatic Patients With COVID-19
|
N/A |